Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing

Dan Lane, Alexander Lawson, Angela Burns, Michel Azizi, Michel Burnier, Donald J.L. Jones, Benjamin Kably, Kamlesh Khunti, Reinhold Kreutz, Prashanth Patel, Alexandre Persu, Wilko Spiering, Stefan W. Toennes, Maciej Tomaszewski, Bryan Williams, Pankaj Gupta, Indranil Dasgupta; Endorsed by the European Society of Hypertension (ESH) Working Group on Cardiovascular Pharmacotherapy and Adherence

ABSTRACT: Nonadherence to antihypertensive medication is common, especially in those with apparent treatment-resistant hypertension (true treatment-resistant hypertension requires exclusion of nonadherence), and its routine detection is supported by clinical guidelines. Chemical adherence testing is a reliable and valid method to detect adherence, yet methods are unstandardized and are not ubiquitous. This article describes the principles of chemical adherence testing for hypertensive patients and provides a set of recommendations for centers wishing to develop the test. We recommend testing should be done in either of two instances: (1) in those who have resistant hypertension or (2) in those on 2 antihypertensives who have a less than 10 mm Hg drop in systolic blood pressure on addition of the second antihypertensive medication. Furthermore, we recommend that verbal consent is secured before undertaking the test, and the results should be discussed with the patient. Based on medications prescribed in United Kingdom, European Union, and United States, we list top 20 to 24 drugs that cover >95% of hypertension prescriptions which may be included in the testing panel. Information required to identify these medications on mass spectrometry platforms is likewise provided. We discuss issues related to ethics, sample collection, transport, stability, urine versus blood samples, qualitative versus quantitative testing, pharmacokinetics, instrumentation, validation, quality assurance, and gaps in knowledge. We consider how to best present, interpret, and discuss chemical adherence test results with the patient. In summary, this guidance should help clinicians and their laboratories in the development of chemical adherence testing of prescribed antihypertensive drugs.

Key Words: adherence • guidelines • hypertension • mass spectrometry • compliance • urine

Hypertension is the most important modifiable risk factor of cardiovascular disease, accounting for 1.16 million deaths and 21.5 million disability-adjusted life-years globally in 2019. Nonadherence to antihypertensive medications is common (rates between 30%–50%) and associated with uncontrolled blood pressure (BP), poor clinical outcomes, and an increased cost to the healthcare system. Nonadherence has been known since the time of Hippocrates, but an important impediment in improving it has been that, until recently, there was the lack of an objective and feasible method to assess nonadherence.

In this guidance article, we summarize the current state of chemical adherence testing (Figure 1), which is a robust technique used to objectively confirm medication ingestion. We aim to provide an understanding and framework for hypertension specialists aiming to develop chemical adherence testing for antihypertensive medications in their centers. We provide pragmatic recommendations that could be applied to suit local health systems with the aim to standardize testing in the future and summarize the gaps in knowledge in the field.

MATERIALS AND METHODS

Up to date, literature were sought from MEDLINE via PubMed, as well as relevant international guidelines, to inform the
recommendations made in this article. Subsequent iterations of the article were reviewed in regular meetings of the authors to reach the consensus on the usefulness and weight of the recommendations. Details of how data were extracted from the medication dispensary databases are outlined in the Supplemental Material (Methods section). Prescription rate data is available on request from the authors.

MEASURES OF NONADHERENCE

Physicians’ perception of whether a patient is adherent to their medication or not has been shown to be no better than flipping a coin. Self-reported measures such as questionnaires suffer from an over-reporting of adherence by patients. Prescription records are used to assess nonadherence in some clinical research studies, although they also tend to over-report adherence, require seamless integration of all electronic pharmacy records, suffer from methodological issues in calculating nonadherence, and do not reflect the current status of nonadherence of a patient. Pill counting is objective but is time-consuming and is dependent on patients remembering to bring their pillboxes with them at their clinic visit. An obvious limitation of this method is that pills may also be taken out but not necessarily ingested. One of the objective methods to assess nonadherence is the use of electronic monitoring systems, such as pill dispensers, which record every time a pill container is opened. This method is generally able to monitor only a single medication per bottle but can provide a dosing history over months or years. Today, it is primarily used for research proposes. The advantages of all above methods may be circumvented in case of intentional nonadherence. Directly observed therapy, or witnessed intake of medications, avoids this potential bias but requires supervision by a senior nurse or a doctor during a day-ward admission and may unintentionally cause severe hypotension. It is also complex to organize for a large population of patients with resistant hypertension and expensive limiting its use in routine care. These methods are summarized in the Supplemental Material (Table S1 in the Supplemental Material).

CHEMICAL ADHERENCE TESTING

New methods of chemical adherence testing have been developed for use as objective measures of
nonadherence to antihypertensive medications. The technique typically uses liquid chromatography–tandem mass spectrometry (LC-MS/MS) to detect medications in patient samples (blood, urine, etc). Such methods represent a considerable improvement in the detection of nonadherence as their implementation has started to fulfill an unmet clinical need. The latest European Society of Cardiology and European Society of Hypertension guidelines state that chemical testing for nonadherence shows "considerable promise but are not widely available." The most recent International Society of Hypertension guidelines put a strong emphasis on screening for nonadherence in management of hypertension and recommend using objective (such as the chemical analysis of blood or urine) rather than subjective methods of detecting nonadherence in clinical practice.

NOMENCLATURE OF ADHERENCE

The World Health Organization recommends using “adherence” to describe the extent to which a person’s behavior (ie, taking prescribed medications) corresponds with agreed-upon healthcare provider recommendations. In the past, adherence was typically described in a pejorative manner that associated the behavior with being difficult or disobedient. For example, “recalcitrant” and “noncompliant” were often used throughout the 20th century to indicate nonadherence. "Concordance" was coined later to deviate from terminology that implicated patient blame. However, “adherence” was considered to be the least paternalistic term (ie, suggests that the patient has a say in their own healthcare and is not just following orders). For the analytical testing of adherence using blood and urine, we recommend using the phrase “chemical adherence testing.”

CURRENT STATUS OF CHEMICAL ADHERENCE TESTING

Number of Centers

Chemical adherence testing is used in a limited number of secondary and tertiary healthcare settings. Although it is not used in primary care, there are data to suggest it is feasible to do so both in the United Kingdom, and internationally. There are also data to show that the test is cost-effective (at £40 or €46/$55 as of 2021, per sample, but this will vary largely between laboratories and countries). The reasons for this lack of uptake could be the lack of awareness and the lack of availability of the test, which we hope will be rectified by this article. Currently, in the United Kingdom, there are several centers with access to this methodology; at least three of these centers receive samples from 60 NHS hospitals. Elsewhere, among the members of the European Society of Hypertension working group on adherence, 14 out of 50 centers regularly perform chemical adherence testing (unpublished result).

POPULATION, SCOPE OF SCREEN, AND ETHICAL CONSIDERATIONS

Who to Screen?

The European Society of Cardiology/European Society of Hypertension recommends that nonadherence be assessed especially in those who have suspected resistant hypertension, which is defined as an uncontrolled hypertension despite optimal or best-tolerated doses of three or more antihypertensive drugs, including a diuretic. In this context, we stipulate suspected resistant hypertension should be denoted as apparent treatment resistance. Nonadherence increases with the number of prescribed antihypertensive medications in a near-linear fashion from 10% when a patient is on a single medication to around 70-80% in those prescribed six medications. Considering this alongside previous European Society of Cardiology/European Society of Hypertension suggestions, we recommend that adherence should be assessed in patients treated for hypertension in the following circumstances:

1. In those with suspected resistant hypertension
2. In those on 2 antihypertensives who have a <10 mm Hg drop in systolic BP on addition of the second antihypertensive medication

The latter threshold is based on data by Wu et al, who reviewed BP-lowering efficacy of monotherapy with main classes of antihypertensive medications and noted (on average) >10 mm Hg drop for each class. Furthermore, after addition of the second antihypertensive, one should wait until the next scheduled clinic visit to consider adherence.

It should be kept in mind that individual adherence profile may vary over time for various reasons, including depression, and that repeated testing may be necessary. However, one should also consider that patients are more likely to take their medications before their outpatient appointment (and as such before chemical testing). This is often termed as white-coat adherence or toothbrush adherence. No adherence measure, including chemical adherence testing, is immune from the problem of measurement reactivity; however, the impact is likely to be small, and this is outweighed by the advantages of such a measure.

When to Screen?

We recommend testing is undertaken early in patients with suspected resistant hypertension before expensive investigations, interventions (ie, renal denervation) as well as treatment escalations/dose alterations. This approach has been found to be cost-effective.
Ethical Implications

Chemical adherence tests should only include medications if they directly affect patient care for the condition being investigated, that is, antihypertensive medications should be tested for if the objective is to improve BP control. Caution should be taken with off-target screening of compounds (eg, drugs of abuse) which could have ethical and legal implications.

The European Workplace Drug Testing Society indicates that sufficient information, meaning, and context of the test should be outlined to the recipient to allow for consent to be given. We recommend that the standard medical practice of verbal informed consent used before any analytical test is sufficient in this situation. However, we recommend that to avoid influencing patient behavior; consent is best taken on the day of sampling. Consent should be recorded in the medical notes, in line with the local governance.

Given that the LC-MS/MS based techniques have the ability to detect a whole plethora of compounds, an argument can be made for the detection and reporting of substances other than those requested by the patient’s doctor, that is, off-target screening of nonantihypertensive substances (over the counter or nonprescribed) that decrease the efficacy of prescriptions. For example, St John’s Wort may increase clearances of medications by enhancing drug metabolism via cytochrome P450 enzymes or excretion via p-glycoprotein. Rifampicin and antiepileptics are also inducers of these proteins. The benefit of off-target screening alongside adherence testing is unknown, although a systematic review found that preventable drug-drug interactions were the cause of 1.1% of all hospital admissions. Another study found unexpected (unprescribed) use of β-adrenoreceptor and renin-angiotensin-aldosterone system blockers in 25% of hypertensive patients. Those patients may be receiving BP-lowering agents such as beta-blockers or RAS-blockers prescribed for cardiovascular disease protection (or postmyocardial infarction) rather than for BP-lowering per se.

We recommend approaching local ethical committees if off-target screening were to be undertaken. Also, hypertension specialists should have the list of medications tested available to show to patients before samples are collected. To mitigate unintended, off-target detection, we propose the implementation of reporting filters for systems that can screen a large library of drugs and metabolites.

Is Chemical Adherence Testing Acceptable to Patients?

A recent study assessing patients’ attitudes and beliefs towards chemical adherence testing found that 91% of patients believed the test was a good idea and one that may be used frequently for the understanding of suboptimal disease control. However, 63% of the patients stated concerns about the impact chemical adherence testing may have on the patient-physician relationship. Testing is, therefore, acceptable from the patients’ perspective, although it is paramount to approach the topic without accusation (see How to Present, Interpret, and Discuss the Results to the Patients).

Composition of the Screening Panel

The medication panel for screening in a clinical setting should be based on local prescription habits, which differ between countries and regions. In the United Kingdom and European Union, 20 drugs describe 95% of dispensed treatments for hypertension. In the United Kingdom, 4 medications span over half of the prescriptions (UK column, rank 1–4, Table 1). In Europe, the pattern is more diverse; 5 drugs represent over 50% of prescribed antihypertensives (European Union column, rank 1–5, Table 1). A US assay that covers 95% of hypertension therapies would likely include medications listed in Table 1. Five medications would also form half of all prescriptions (US column, rank 1–5, Table 1). Information on how this data were selected is outlined in the Supplemental Material.

Therefore, we recommend that the top 95% of locally prescribed medications would be an acceptable screening panel for most clinics. At a minimum, the screen should include at least five of the most prescribed medications. This repertoire could be extended over time.

Evidently, panels for research that are used as part of international trials could include a variety of drugs that are different from drugs prescribed in a country or region. It is also worth noting the complexity of data interpretation increases with larger panels.

The potential of chemical adherence testing in combination pills has been shown in a recent pilot study. Detection of only one of the pill constituents would likely indicate sporadic adherence. For example, in an amlodipine/hydrochlorothiazide combination, where amlodipine is eliminated from the body slowly and hydrochlorothiazide is eliminated quickly, the sole detection of amlodipine in chemical adherence testing would suggest intermittent dosing. We recommend hydrochlorothiazide should be included in the screening panel as it is a commonly encountered as a combination pill.

Multicentre studies, or laboratories that partake in external quality assessment, should consider including those drugs (N=8; amlodipine, enalapril, furosemide, lisinopril, losartan, propranolol, ramipril, and spironolactone) that are repeated in United Kingdom, European Union, and US lists to allow the sharing techniques, experience, and samples across centers. Furthermore, prescribing patterns are liable to change and, to future-proof the
Therapies that control hypertension describe only a portion of medications that could be targeted for adherence testing in patients at risk of cardiovascular disease, as people with hypertension are likely to have multi-morbidities including heart diseases, diabetes, and dyslipidemia. The usage of chemical adherence testing in these conditions is currently being established.39,40

**ANALYTICAL METHOD**

Several different techniques can be used to detect, or quantify, drugs from extracted matrices but for many clinical laboratories, LC-MS/MS has replaced other conventional chromatographic systems. This technique is available in most university laboratories. The instrument costs ≈£250 000 (€290 302 or $346 349 as of 2021) and is generally purchased on lease/rental model. LC-MS/MS screens can detect all classes of antihypertensive drugs or their metabolites in urine or plasma. Published methods have shown the detection of 9,41 13,42 14,43 23,44 40,4 46,45 or >54 antihypertensives. The panel size can be readily increased, where running costs are largely unaffected, though additional chemical standards (≈£150/€177/$209 each) will be required. Lower limits of detection using LC-MS/MS are typically less than 1 ng/mL, although lower ranges can be obtained with more advanced MS technologies. When reporting results around extremely low lower limits of detections, one must be mindful that basal levels of antihypertensives may indicate sporadic adherence—this idea is explored in the Pharmacokinetics section.

The next level of instrumentation is high resolution (HR)–MS—an MS platform with higher resolving power (<0.001 Da) like a quadrupole time of flight or an Orbitrap—offers similar advantages to MS/MS in excellent sensitivity and sample preparation, but offers

---

**Table 1. Annual Prescription Rates for Hypertension Medications in the United States (US; 2017), United Kingdom (UK; 2018), and European Union (EU; 2020)**

| Rank | US prescriptions 2017 | UK prescriptions 2018 | EU prescriptions 2020 |
|------|-----------------------|-----------------------|-----------------------|
|      | Chemical name         | Items*                | Chemical name         | Items                  | Chemical name | Items                 | Cumulative % | Cumulative % | Cumulative % |
| 1    | Lisinopril            | 104 779 319           | 19.9                  | Amlodipine            | 29 052 338     | 17.0                  | Bisoprolol     | 7 907 237 153 | 15.9        |
| 2    | Amlodipine            | 72 508 879            | 33.7                  | Ramipril              | 28 605 025     | 33.8                  | Ramipril      | 5 480 622 545 | 27.0        |
| 3    | Metoprolol            | 68 243 168            | 46.7                  | Bisoprolol            | 23 625 562     | 47.7                  | Amlodipine    | 5 095 414 027 | 37.2        |
| 4    | Losartan              | 51 989 444            | 56.6                  | Bendroflumethiazide†  | 9 968 237      | 53.5                  | Metoprolol    | 4 534 102 285 | 46.4        |
| 5    | Hydrochlorothiazide   | 42 037 081            | 64.6                  | Losartan              | 9 842 443      | 59.3                  | Candesartan   | 2 787 860 664 | 52.0        |
| 6    | Carvedilol            | 22 974 069            | 69.9                  | Lisinopril            | 8 866 133      | 64.5                  | Nebivolol     | 2 200 634 873 | 56.4        |
| 7    | Atenolol              | 20 208 476            | 72.8                  | Atenolol              | 7 974 627      | 68.7                  | Enalapril     | 1 953 629 115 | 60.4        |
| 8    | Propranolol           | 17 790 917            | 76.1                  | Candesartan           | 6 887 553      | 72.7                  | Lercanidipine | 1 883 278 123 | 64.2        |
| 9    | Spironolactone        | 11 641 507            | 78.4                  | Doxazosin             | 6 600 406      | 76.6                  | Perindopril   | 1 395 952 158 | 67.0        |
| 10   | Diltiazem             | 10 504 285            | 80.4                  | Propranolol           | 5 287 584      | 79.7                  | Indapamide    | 1 346 020 255 | 69.7        |
| 11   | Clonidine‡            | 10 239 431            | 82.3                  | Indapamide            | 4 618 639      | 82.4                  | Losartan      | 1 287 651 118 | 73.2        |
| 12   | Valsartan             | 9 231 280             | 84.1                  | Perindopril           | 4 541 353      | 85.0                  | Carvedilol    | 1 263 629 967 | 74.9        |
| 13   | Benazepril#           | 7 163 351             | 85.4                  | Felodipine‡           | 3 680 683      | 87.2                  | Spirolonactone | 1 213 840 475 | 77.3        |
| 14   | Hydralazine‡          | 7 117 426             | 86.8                  | Diltiazem             | 2 736 225      | 88.8                  | Valsartan     | 1 023 788 822 | 79.4        |
| 15   | Nifedipine            | 6 213 121             | 88.0                  | Spirolonactone        | 2 702 441      | 90.4                  | Telmisartan§  | 947 591 995  | 81.3        |
| 16   | Enalapril             | 6 121 954             | 89.1                  | Lercanidipine         | 2 491 599      | 91.9                  | Irbesartan    | 927 910 758  | 83.2        |
| 17   | Guanfacine‡           | 5 451 594             | 90.2                  | Nifedipine            | 1 845 850      | 92.9                  | Lisinopril    | 908 633 973  | 85.0        |
| 18   | Ramipril              | 5 318 556             | 91.2                  | Irbesartan            | 1 841 482      | 94.0                  | Propranolol   | 882 513 822  | 86.8        |
| 19   | Verapamil             | 4 628 812             | 92.0                  | Enalapril             | 1 662 282      | 95.0                  | Hydrochlorothiazide | 875 562 021 | 88.5        |
| 20   | Nebivolol             | 4 473 865             | 92.9                  | Doxazosin             | 788 105 735    | 90.1                  | An Aldolol    | 782 946 672  | 91.7        |
| 21   | Doxazosin             | 4 370 838             | 93.7                  | Atenolol              | 782 946 672    | 91.7                  | Olmesartan§   | 656 225 749  | 93.0        |
| 22   | Chlorthalidone‡       | 3 601 956             | 94.4                  | Nelson§               | 544 212 462    | 94.1                  | Verapamil     | 544 212 462  | 94.1        |
| 23   | Terazosin‡            | 2 936 434             | 95.0                  | Moxonidine§           | 522 969 802    | 95.2                  | Moxonidine‡   | 522 969 802  | 95.2        |

Medications cover 95% of all dispensed drugs with hypertension as one of the indications. US data sourced from the Medical Expenditure Panel Survey (MEPS) HC-197A: 2017 Prescribed Medicines File—UK data sourced from National Health Service (NHS) Digital, Prescription Cost Analysis–England, 2018.36 All dose amounts were included, and only the most prevalent formulations were used. Polypill combinations were excluded.

*Weighting factor defined by US demographic data (PERWT71F) has been used to represent 321 529 965 people.

†Medications independent in United States.

‡Medications independent in United Kingdom.

§Medications independent in European Union.
larger screen sizes (eg, >1000 medications) without compromising analytical performance. HR-MS has been used in the field for the simultaneous detection of 49 drugs (plus metabolites) with limits of detection similar to MS/MS methods.46 However, HR-MS technique is more expensive than LC-MS/MS (≈ £400 000, €464 540, or $554 158) and requires personnel with a considerably higher degree of experience with mass spectrometry, which has to be considered if implementation and development of such procedures are planned.

**Immuoassay**

Immuoassay is commonly used for high throughput screening of urine and oral fluid samples for drugs of abuse. They use antibodies, which can cross-react with certain drug classes. The advantage of immunoassay screening is their ease of use, throughput, and sensitivity. The main disadvantage is their lack of specificity, with positive results requiring confirmation by MS platforms. For antihypertensive screening, some groups have developed immunoassays for a particular antihypertensive medication,47–49 but none have developed a panel suitable for adherence testing. Commercial support would make development, validation, and automation of immunoassays easier. However, the present market for adherence testing is not large enough to gain significant interest of industry.

In summary, we recommend that due to the sensitive analyses required for clinically useful and comprehensive testing, currently only LC-MS/MS or HR-MS offer specifications that can meet adherence testing criteria. HR-MS offers several advantages over LC-MS/MS but currently is less ubiquitous than LC-MS/MS.

**ANALYTICAL TARGETS**

Adherence assays in both urine and blood should aim to be as sensitive as possible, aiming for a lower limits of detection of <10 ng/mL for all medications. For some drugs, targeting parent drug, metabolite, or a combination of the two will help to extend the detection window for the medications. The ratio of parent drug to metabolite may also give insight into white-coat adherence. A list of useful mass spectral characteristics (transitions) for the use by any laboratory that intends to set up an MS assay for adherence screening to antihypertensive medications, is available in the Supplemental Material (Table S2).

**REQUESTING THE TEST**

When requesting an adherence screen, information on the request form should ideally include demographic factors that can affect pharmacokinetics of the medications, such as age, sex, ethnicity, body mass index along with other useful information such as time of sample collection, timing and dose of medications, and a list of all prescribed medications. If feasible, estimated glomerular filtration rate and liver function may be added. Where possible, the request should be linked with electronic patient records. Errors in prescriptions recorded by the requesting doctor may result in apparent positive off-target screening; hence, it is important that the list of medications that a patient is prescribed is detailed accurately when requesting the test.

**SAMPLE TYPE**

The type of biomatrix collected for medication screening will impact the detection limits, sample preparation, and reporting. Previous work has indicated that urine and blood assays are the most useful in adherence testing.50 A comparison of these matrices is noted in the Supplemental Material (Table S3).

**Blood Assays**

The results of chemical adherence testing by blood or urine can be reported as a qualitative (present/not present) or a quantitative measure. Blood is less often used for qualitative analysis in adherence testing51–53 but is more frequently used for quantification.34,46,54–58 Certain groups have started quantifying antihypertensive drugs and comparing the results against the established peak (Cmax) and minimal/trough (Cmin) plasma drug concentrations.45,54,57,59 These may provide a putative range indicative of regular intake (below steady-state range in Figure 2). A recent meta-analysis has shown great heterogeneity in plasma trough concentrations, and hence, caution is advised in using quantitative methods to ascertain adherence status.50 From a practical point of view, quantitative analyses require considerably more use of laboratory resources.

Elsewhere, groups have introduced pin-prick sampling associated with dried matrix spotting techniques for antihypertensive detection to avoid venepuncture methods.55,61 The approach is less invasive and is promising for those interested in developing a blood-based method.

**Urine Assays**

Urine chemical adherence tests are mostly qualitative.4,17,51,52,54–58 Although, some groups have published quantitative methods.44,58 Concentrations do not necessarily reflect when the drug was administered due to variances in hydration, pH, and frequency of urination. However, the collection of urine is noninvasive and easy to obtain in larger quantities. The matrix generally requires less preparation before being suitable for analysis compared with blood derivatives as phospholipids...
and other interfering compounds are absent. Simple dilute and shoot methods for urinary detection of 23 antihypertensives before liquid chromatography LC-MS/MS analysis have been published. The relative ease of preparation allows timely processing in the lab, thus, has a high ceiling for throughput at minimal costs. Theoretically, factors such as the amount of excretion of a drug in urine may affect the results, although an observational study with limited demographic data failed to confirm such effect. Furthermore, prospective studies are needed to confirm this finding.

In brief, we recommend the use of qualitative methods using either urine or blood samples to detect drug presence. Urine is often easier to acquire, although blood may allow more information to be sought on ingestion time and dosing regularity, given further research validates such techniques. Dried blood spots and other equivalent matrices may be considered if the laboratory has the required expertise.

PHARMACOKINETICS

In chemical adherence testing, some researchers have suggested drugs with extremely short or long elimination half-lives may incur false negative/positives. For example, amlodipine is cleared slowly (half-life 34–50 hours), thus dosing could be sporadic but still be analytically positive a week after the last ingestion. Conversely, hydrochlorothiazide is cleared rapidly (half-life 6.4 hours), and sporadic dosing was suggested to appear analytically negative. However, recent report demonstrated no correlation between half-life and adherence rates for common antihypertensive medications in urine (Figure 3). This may seem counterintuitive, although medications with short half-lives are often indicated in higher concentrations or in multiple daily doses, so adherent patients would likely be detected by the test. The fraction of renal elimination is also important for those drugs that are excreted in urine. Of note, people with impaired renal function may have altered clearances.

In blood assays, can be used as a threshold for sporadic/regular dosing determination. For each drug has been established using literature, although recent evidence has highlighted the large heterogeneity of in different studies. To avoid misclassification, some groups have used merely as a basis to optimize cutoffs for their local population. Other groups have optimized cutoffs on an individual basis (rather than population), using each patients' dose alongside scoped pharmacokinetics to estimate a dose-dependent concentration. Further work, including pharmacokinetic modeling using data from adherent patients with hypertension, would help provide more information on these aspects.

Therefore, we recommend that reports mention the half-lives of medications (from published literature) and further research on the impact of pharmacokinetics on adherence status is undertaken.

SAMPLE REQUIREMENTS

Currently, there is no data on the optimal time of sample collection and further research is needed in this area. Therefore, for pragmatic reasons, we recommend collecting samples when the patient attends a clinic. The minimum amount needed for urine analysis is small (<1.5 mL), although collection should be done in <20 mL standard universal containers. For blood samples, at least 1 mL should be collected in lithium heparin or, alternatively, an EDTA tube may be used for the collection of plasma. Serum may also be collected, as well as dried blood spot sampling (where the facilities for analysis of such samples are available).

SAMPLE STABILITY AND TRANSPORT

In a spoke-hub distribution laboratory model, samples are sent to a main site for testing. Delivery conditions are variable, so medication stability should be considered. Research results on stability are inconsistent.
For example, antihypertensive drugs (N=29) in urine are stable at room temperature for three days. In another study, the stability of 23 antihypertensive medications was investigated. This study found the majority of drugs were stable in urine under a variety of conditions with significant losses seen for nifedipine (unstable when stored at 25 °C for 1 day) and bendroflumethiazide (unstable when stored at 25 °C for 1 day and when stored at 4 °C for 7 days). However, both drugs were stable when stored at −20 °C for 28 days. Another study of 6 antihypertensives found they were unstable at high pH but stable at a variety of temperatures.

We recommend that urine samples be stored at 4 °C after collection—but can be transported by ordinary post within three days of sampling for most antihypertensives (nota bene consider transporting on ice for nifedipine and bendroflumethiazide). Further research should investigate the stability of medications not previously reported. Once in the laboratory, samples can be stored at −20 °C for at least 4 weeks before analysis.

The stability of antihypertensive drugs in blood has not been investigated as extensively. One group demonstrated long-term stability at −80 °C from a panel of 20 analytes in plasma. Three-hour room temperature stabilities were poor for some drugs, including captopril, hydralazine, and nifedipine. Catalytic ability of blood can be retained as free proteins can preserve their esterase function. Storing these biomatrices cold (≤4 °C) will help to lessen these effects.

To decrease the effect of these enzymes, we recommend that blood should be centrifuged and the supernatant decanted, if possible. Serum or plasma should be stored frozen if possible; whole blood should not be frozen (to avoid hemolysis) but stored refrigerated. Shipping should take as short as possible and samples should be kept cool. Amber vials or other light exclusion techniques may also be used, especially in view of a possible degradation of dihydropyridine calcium channel antagonists, although their efficacy is not well-understood for all antihypertensives.

Dried matrices can be sent by ordinary post and can be stored at room temperature.

**LABORATORY CONSIDERATIONS**

Important aspects for the laboratory including sample preparation, validation, and external quality assurance have been outlined within the Supplemental Material.

**FORMAT OF REPORTS**

Nonadherence reports should be designed with the user in mind, with results being clear and concise for ease of interpretation. The technique used in the assay should be stated. Ideally, the list of hypertension medications prescribed should be detailed next to whether the drug was detectable or not detectable for the clinician to equate the result to adherence.

We recommend that for qualitative assays, the report should state the medication as “detected” or “not detected,” and for quantitative reports, the level of drug detected alongside the putative range for each drug should be noted. Cases around and below the putative range should be noted in the report as certain factors (eg, renal disease) may influence the concentration of excreted drug. For a comprehensive report, the drugs that were not detected should be given as “negative (< lower limits of detection ng/mL)” and the prescribed drugs that were not covered by the analytical procedure should be mentioned.

The report may also contain an explanation that it can only conclude on the presence or absence of a drug over the half-life of medication and that period should be stated for the medication. It is not currently possible to predict ingestion of the dose given a concentration. Printing the half-life alongside the result provides context.
if not detected, ie, >4 half-lives typically provides enough time to clear a single dose. The report should also state that malabsorption, among other reasons (see Fallacies of Chemical Adherence Testing and Gaps in Knowledge), maybe a reason for nondetection of medications.

HOW TO PRESENT, INTERPRET, AND DISCUSS THE RESULTS TO THE PATIENTS

It is imperative to give feedback on the test, regardless of result. This is designed to reinforce positive behavior where appropriate. In our experience, the results allow an open, nonjudgemental discussion about adherence. Most patients accept that they are nonadherent once the discussion is initiated. Although nonadherence is common, this aspect is not covered well in medical school training, therefore, clinicians may not feel comfortable about discussing the report of nonadherence with patients. Patients should be approached in an open-minded manner with the view to understand the reasoning for their nonadherence.

We recommend covering the common causes of nonadherence, such as forgetfulness, side-effects, costs, and patients’ knowledge and beliefs about their illness and need to take medications. Also, it is useful to record nondetection (rather than nonadherence) by chemical testing in the patients’ medical notes or correspondence. This information, if available to other clinicians, will avoid unnecessary investigations or potential complications if an admitted patient is given all their antihypertensives that he/she was not previously adherent to.

Patients on multiple medications who have tested positive for all but one medication (ie, 5/6) should be carefully reviewed. These patients may be considered adherent, as nondetection may be due to the medications pharmacokinetics. If there is persistent disagreement about the adherence status, a direct observed therapy could be undertaken.

Chemical adherence testing may only be the initial step of the adherence monitoring process since repeated measures on the same patient may be required.

FALLACIES OF CHEMICAL ADHERENCE TESTING AND GAPS IN KNOWLEDGE

Known contributors to low medication levels, other than nonadherence, have been previously outlined by Berra et al. Since this publication, several contributors have been addressed (primarily the preanalytical artifacts). However, research is still required on issues with pharmacokinetics and effectors thereof (eg, gastrointestinal tract alterations on adsorption). Although there are data from observational studies, there is a need for well-designed prospective studies to answer the questions about the relationships between various pharmacokinetic parameters such as volume of distribution, half-life, urine excretion rate, and nondetection of drugs in blood or urine. Similarly, research is needed to study the effects of genetic polymorphisms in cytochromes P450, P-glycoprotein, and other drug transporters that effect pharmacokinetics on chemical adherence screening.

Observational studies have shown that chemical testing followed by discussion of results with a nonadherent patient, improves adherence status and BP. Further evidence in the form of randomized control trials is needed as long-term outcomes after chemical adherence testing are poorly researched. The OUTREACH trial (https://www.clinicaltrials.gov; Unique identifier: NCT03293147) is aimed to answer this question.

Studies have shown that there are not only reasonable congruities but also differences between detection of medication in urine versus blood. Larger studies are needed to study correlation between nonadherence results based on urine and blood samples, but if there is a good correlation between blood and urine chemical nonadherence results, this would not necessarily mean that these can be used interchangeably. Further studies are needed on the usefulness of quantitative measurement of drugs in adherence screening. Also, different matrices (eg, dried blood and urine, saliva, hair) should be explored to overcome the frailties in collection and stability. Long-term monitoring is also poorly researched. Dried matrices may allow for at-home sampling which could enable conduct of such a study.

Having multiple methods to assess adherence is always desirable. Self-reporting alongside chemical adherence testing can often provide context to the bioassay data. For example, adherent, older patients with limited mobility may forego their diuretics on the day of their clinic visit to circumvent needing to urinate outside their home. We suggest chemical adherence testing be used to triangulate with other assessments, especially those that gather patient perspective.

OTHER CONSIDERATIONS INCLUDE

- Does the ratio of parent drug to metabolite indicate long-term adherence?
- What is the optimal time of sample collection? For example, is an early morning urine sample better than collecting samples when patient comes to clinic? Similarly, should the blood sample be collected at the expected trough concentration (ie, before the next dose)?

SUMMARY OF RECOMMENDATIONS

We have outlined some considerations for groups interested in developing a chemical adherence test for clinical use. The drug panel and the aim of the test (qualitative or
Table 2. Summary of Recommendations for Developing and Implementing a Chemical Adherence Test

| Summary of recommendations                                                                 |
|-------------------------------------------------------------------------------------------|
| Chemical adherence testing should be used as the terminology for assessing adherence by means of analysis of biofluids (eg, urine or plasma/serum) |
| Verbal consent should be obtained, and the scope of the test must be outlined. Ideally, this should be done on the same day as sampling |
| Chemical adherence testing should be done:                                                   |
| In those with suspected resistant hypertension (true treatment resistance requires exclusion)  |
| In those on two antihypertensives who have a less than 10 mm Hg drop in systolic blood pressure on addition of the second antihypertensive medication |
| The most common locally prescribed antihypertensive medications should be included in the assays scope |
| Liquid chromatography-mass spectrometry platforms should be used for analysis               |
| Request forms should include detailed medication plan and time of last dose before sampling; other patient characteristics can be collected too |
| Qualitative screening using urine or blood is preferred over quantitative analysis as cutoffs (eg, for Cmax) cannot be sourced from literature |
| Samples should be sent and stored on ice where pragmatic; room temperature delivery of urine and dried blood is possible |
| Reports should detail in simple terms which drugs have been detected and their putative ranges where applicable along with the drugs not detected and those that were not covered by the assay |
| Feedback of the result must be given, regardless of the result                                |
| Discussion of the results with patients should take place in nonconfrontational manner after excluding medical reasons for nondetection of medications. |
| Other measures, especially those that gain the patients' perspective (eg, self-report) should be considered alongside chemical adherence testing to give the full context to the results. |
| Further research is needed on impact of pharmacokinetic parameters, number of tests required, impact of the tests on change in adherence behavior, and correlation with long-term outcomes |

ARTICLE INFORMATION

Affiliations
The Department of Cardiovascular Pathology and Metabolic Diseases, Level 4, Sandringham Building, Leicester Royal Infirmary, United Kingdom (D.L., PP, PG). Leicester Diabetes Centre, University of Leicester, Leicester General Hospital, Leicester, United Kingdom (D.L., K.K.). Department of Clinical Chemistry, Immunology and Toxicology, Heartlands Hospital University Hospitals Birmingham, United Kingdom (AL). Department of Clinical Biochemistry, Queen Elizabeth University Hospital, Glasgow, United Kingdom (AB). Université de Paris, Inserm CIC1418, Paris, France (MA.). APHP, Hypertension Unit, Hôpital Européen Georges Pompidou, Paris, France (MA.). Service of Nephrology and Hypertension, University Hospital, Lausanne, Switzerland (MB.). Department of Cardiovascular Sciences, University of Leicester. Cardiovascular Research Centre, Glenfield Hospital, Leicester, United Kingdom (DJLJ, PP, PG). Université de Paris, France (BK). APHP Pharmacology Unit, Hôpital Européen Georges Pompidou, Paris, France (BK). Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Klinische Pharmakologie und Toxikologie, Germany (RKJ). Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium (Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain (AP). Department of Vascular Medicine, University Medical Center Utrecht, Utrecht University, the Netherlands (WS.). Institute of Legal Medicine, Department of Forensic Toxicology, University Hospital, Goethe University, Frankfurt, Germany (S.WT). Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom (MT.). Manchester Heart Centre, Manchester University National Health Service Foundation Trust, United Kingdom (MT.). Department of Cardiovascular Sciences, University College London, United Kingdom (B.W.). Renal Unit, Heartlands Hospital, Birmingham and Warwick Medical School, University of Warwick, Coventry, United Kingdom (ID.).

REFERENCES
1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76:2982–3021. doi: 10.1016/j.jacc.2020.11.010
2. Hameed MA, Dasgupta I. Medication adherence and treatment-resistant hypertension: a review. Drugs Context. 2019;8:212560. doi: 10.7573/dic.212560
3. Lawson AJ, Hameed MA, Brown R, Cappuccio FP, George S, Hinton T, Kapil V, Lenart J, Lobo MD, Martin U, et al. Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. J Hypertens. 2020;38:1165–1173. doi: 10.1097/HJH.0000000000002938
4. Tomaszewski M, White C, Patel P, Masca N, Daman R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100:855–861. doi: 10.1136/heartjnl-2013-305063
5. Gupta P, Patel R, Strauch B, Lai FY, Akbarov A, Gulsin GS, Beech A, Mařešlová V, Topham PS, Stanley A, et al. Biochemical screening for non-adherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017;70:1042–1048. doi: 10.1161/HYPERTENSIONAHA.117.09631.
6. Koldaivelu K, Leiden BB, O’Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. Eur Heart J. 2014;35:3267–3276. doi: 10.1093/eurheartj/ehu364
7. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by discharge groups: a systematic review. BMJ Open. 2018;8:e016982. doi: 10.1136/bmjopen-2017-016982
8. Jones WHS. Hippocrates, with an English Translation by WHS Jones. London: Heinemann. 1923; 296–297.
9. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, Agoritsas T, Mistry N, Iorio A, Jack S, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014:CD000011. doi: 10.1002/14651858.CD000011.pub4
10. Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res. 2012;12:270. doi: 10.1186/1472-6963-12-270
11. Durand H, Hayes P, Morrissey EC, Newell J, Casey M, Murphy AW, Molloy GJ. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens. 2017;35:2346–2357. doi: 10.1093/ hypertension/79.12–23. DOI: 10.1161/HYPERTENSIONAHA.121.17596
48. Al-Hakiem MH, White GW, Smith DS, Landon J. Direct determination of propranolol in serum or plasma by fluoroimmunoassay. Ther Drug Monit. 1981;3:159–165. doi: 10.1097/00007691-198102000-00007

49. Robinson JD, Lewis S. The Analysis of ACE Inhibitors by Immunoassay. 1988:143–148.

50. Lane D, Patel P, Khunti K, Gupta P. Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening. Patient Prefer Adherence. 2019;13:537–547. doi: 10.2147/PPA.S162215

51. Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D, Kindermann I, Ukena C, Burnier M, Wagenpfeil S, et al. Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Rest Cardiol. 2015;104:1097–1105. doi: 10.1002/s00392-015-0905-5

52. Azizi M, Pereira H, Hamdidouche I, Monge M, Bobrie G, Delsart P, Mounier-Véhier C, Courand PY, Lantelme P, et al; DENERHTN Investigators. Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. Circulation. 2016;134:847–857. doi: 10.1161/CIRCULATIONAHA.116.029292

53. de Jager RL, van Maarseveen EM, Bots ML, Blankstijn PJ; SYMPATHY investigators. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018;84:18–24. doi: 10.1111/bcp.13402

54. Jones ESW, Lesosky M, Blockman M, Castel S, Declotted EH, Schwager SJU, Sturrock ED, Wesner L, Rayner BL. Therapeutic drug monitoring of amiodarine and the Z-FHHL/HHHL ratio: Adherence tools in patients referred for apparent treatment-resistant hypertension. S Afr Med J. 2017;107:887–891. doi: 10.7196/SAMJ.2017.107.12268

55. Bernieh D, Lawson G, Tanna S. Quantitative LC-HRMS determination of selected cardiovascular drugs, in dried blood spots, as an indicator of adherence to medication. J Pharm Biomed Anal. 2017;142:232–243. doi: 10.1016/j.jpba.2017.04.045

56. Tanna S, Alalaiji A, Bernieh D, Lawson G. Volumetric absorbptive microsampling (VAMS) coupled with high-resolution, accurate-mass (HRAM) mass spectrometry as a simplified alternative to dried blood spot (DBS) analysis for therapeutic drug monitoring of cardiovascular drugs. Clinical Mass Spectrometry. 2018;10:1–8.

57. Ritscher S, Hoyer M, Wunder C, Obermüller N, Toennes SW. Benefit of serum drug monitoring complementing pharmaceutical monitoring in the assessment of treatment adherence: a meta-analysis. Hypertension. 2021;77:85–93. doi: 10.1161/HYPERTENSIONAHA.120.16061

58. Balas G, van der Leij F, van der Meer IM, Sweelinck M, van der Maas P, van Schie CA, van der Vendel T, Pleviers S, et al. Impact of drug holidays on adherence to cardiovascular drugs. Acta Cardiol. 2019;74:143–147. doi: 10.2147/bjpr.2018.04.020

59. Groenland EH, van Kleef MEAM, Bots ML, Visseren FLJ, van der Elst KCM, Spiering W. Plasma trough concentrations of antihypertensive drugs for the assessment of treatment adherence: a meta-analysis. Hypertension. 2020;77:95–103. doi: 10.1161/HYPERTENSIONAHA.120.16061

60. Peeters LEJ, Feyz L, Boersma E, Daemen J, van Gelder T, Koch BCP, Versmissen J. Clinical applicability of monitoring antihypertensive drug levels in blood. Hypertension. 2020;76:78–86. doi: 10.1161/HYPERTENSIONAHA.120.15058

61. Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH. Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening exemplified for cardiovascular drugs. Anal Chem Acta. 2015;891:221–233. doi: 10.1016/aca.2015.08.018

62. Pucci M, Martin U. Detecting non-adherence by urine analysis in patients with uncontrolled hypertension: rates, reasons and reactions. J Hum Hypertens. 2017;31:253–257. doi: 10.1038/jhh.2016.69

63. Hamidouche I, Jullien V, Boubouyrie P, Billaud E, Azizi M, Laurent S. Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients. J Hypertens. 2017;35:1891–1899. doi: 10.1097/HJH.0000000000001402

64. Durand H, Hayes P, Harhen B, Conneely A, Finn DP, Casey M, Murphy AW, Molloy GJ. Medication adherence for resistant hypertension: Assessing theoretical predictors of adherence using direct and indirect adherence measures. Br J Health Psychol. 2018;23:949–966. doi: 10.1111/bjhp.12392

65. Lane D, Alghamdi R, Muscat M, Kaur MA, Davis T, Cole R, Patel P, Tomaszewski M, Gupta P. The diagnosis of non-adherence in hypertension using a urine biochemical screen is unaffected by drug pharmacokinetics. Eur Heart J. 2019;40(suppl_1):ehj748.0070. doi: 10.1093/euheartj/ehj748.0070

66. Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care. 2012;16:R136. doi: 10.1186/cc11441

67. Niemeyer C, Hasenfuss G, Wais L, Knuhl H, Schäfer-Korting M, Mutschler E. Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol. 1983;24:661–666. doi: 10.1007/BF00542218

68. Burns AD, Lane D, Cole R, Patel P, Gupta P. Cardiovascular medication stability in urine for non-adherence screening by LC-MS-MS. J Anal Toxicol. 2019;43:325–329. doi: 10.1093/jat/bky090

69. Burns A, Iqbal A, Mulgarn G, et al. The effect of sample tube type, pH, storage time and temperature on antihypertensive non-adherence results by quantitative LC-MS-MS. MSACL EU 2019. 2019.

70. Reed GA. Stability of drugs, drug candidates, and metabolites in blood and plasma. Curr Pharm Biochem. 2016;75:76–1. 76.12. doi: 10.1002/cpbi.16

71. Baranda AB, Alonso RM, Jiménez RM, Weinnmann W. Instability of calcium channel antagonists during sample preparation for LC-MS-MS analysis of serum samples. Forensic Sci Int. 2006;156:239–34. doi: 10.1016/j.forsciint.2004.11.014

72. US Department of Health and Human Services Food and Drug Administration. Bioanalytical method validation guidance for industry. 2018.

73. Scientific Working Group for Forensic Toxicology, Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology. J Anal Toxicol. 2013;37:452–474.

74. Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. 2007;165:216–224. doi: 10.1016/j.forsciint.2006.05.021

75. Honour JW. Development and validation of a quantitative assay based on tandem mass spectrometry. Ann Clin Biochem. 2011;48(pt 2):97–111. doi: 10.1258/abc.2010.010176

76. Arndt T. Urine-creatinine concentration as a marker of urine dilution: reflectionis using a cohort of 45,000 samples. Forensic Sci Int. 2009;186:48–51. doi: 10.1016/j.forsciint.2009.01.010

77. Berra E, Azizi M, Capron A, Heijenga G, Rabbia F, Kjeldsen SE, Staessen JA, Wallemacq P, Persu A. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68:297–306. doi: 10.1161/HYPERTENSIONAHA.116.07464

78. Ritscher S, Hoyer M, Georges C, Wunder C, Wallemacq P, Persu A, Obermüller N, Toennes SW. Benefit of serum drug monitoring complementing urinary analysis to assess adherence to antihypertensive drugs in first-line therapy. PLoS One. 2020;15:e0237383. doi: 10.1371/journal.pone.0237383

79. Ritscher S, Georges C, Wunder C, Wallemacq P, Persu A, Toennes SW. Assessment of adherence to diuretics and β-blockers by serum drug monitoring in comparison to urine analysis. Blood Press. 2020:1–8.

80. Gupta P, Patel P, Tomaszewski M. Measurements of antihypertensive medications in blood and urine. Drug Adherence in Hypertension and Cardiovascular Protection. 2018;29:41. doi: 10.1007/978-3-319-76593-8_4